It is effective in approximately 10–20% of CRC patients; the other patients show cetuximab resistance due to gene mutations in downstream EGFR effectors, including KRAS, phosphoinositide-3-kinase catalytic subunit alpha (PI3KCA), phosphatase and tensin homolog (PTEN), and BRAF [7]. Here, EGFR is linked to colorectal carcinoma.